Výsledky vyhledávání - "Malmström, C."

Akademický článek

How to stop disproportionation of a hydrochloride salt of a very weakly basic compound in a non-clinical suspension formulation.

Autor: Ojala K; Division of Pharmaceutical Chemistry and Technology, Industrial Pharmacy, University of Helsinki, P.O. Box 56, 00014 University of Helsinki, Finland; Orion Pharma, Orionintie 1 A, 02200 Espoo, Finland. Electronic address: krista.em.ojala@helsinki.fi., Salmia J; Orion Pharma, Orionintie 1 A, 02200 Espoo, Finland., Shevchenko A; Orion Pharma, Orionintie 1 A, 02200 Espoo, Finland; Particle Analytical ApS, Agern Alle 3, DK-2970 Hørsholm, Denmark., Ylikotila J; Orion Pharma, Orionintie 1 A, 02200 Espoo, Finland., Korjamo T; Orion Pharma, Orionintie 1 A, 02200 Espoo, Finland., van Veen B; Orion Pharma, Orionintie 1 A, 02200 Espoo, Finland., Koistinen P; Orion Pharma, Orionintie 1 A, 02200 Espoo, Finland., Malmström C; Orion Pharma, Orionintie 1 A, 02200 Espoo, Finland., Laakso S; Orion Pharma, Orionintie 1 A, 02200 Espoo, Finland., Bansal I; Aurigene Discovery Technologies Limited, E-City, Phase-2, Bangalore 560100, Karnataka, India., Samiulla DS; Aurigene Discovery Technologies Limited, E-City, Phase-2, Bangalore 560100, Karnataka, India., Juppo A; Division of Pharmaceutical Chemistry and Technology, Industrial Pharmacy, University of Helsinki, P.O. Box 56, 00014 University of Helsinki, Finland.

Publikováno v: International journal of pharmaceutics [Int J Pharm] 2021 Sep 05; Vol. 606, pp. 120875. Date of Electronic Publication: 2021 Jul 15.

Zobrazit plný text záznamu

Akademický článek

Advancements in Virtual Bioequivalence: A Systematic Review of Computational Methods and Regulatory Perspectives in the Pharmaceutical Industry.

Autor: Alotaiq, Nasser¹ (AUTHOR) naalotaiq@imamu.edu.sa, Dermawan, Doni² (AUTHOR) doni.dermawan.stud@pw.edu.pl

Publikováno v: Pharmaceutics. Nov2024, Vol. 16 Issue 11, p1414. 18p.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Predicting the effect of prandial stage and particle size on absorption of ODM-204.

Autor: Ojala K; Orion Corporation, Orion Pharma, Finland. Electronic address: krista.ojala@orionpharma.com., Schilderink R; Triskelion B.V., the Netherlands., Nykänen P; Orion Corporation, Orion Pharma, Finland., van Veen B; Orion Corporation, Orion Pharma, Finland., Malmström C; Orion Corporation, Orion Pharma, Finland., Juppo A; Division of Pharmaceutical Technology and Industrial Pharmacy, University of Helsinki, Finland., Korjamo T; Orion Corporation, Orion Pharma, Finland.

Publikováno v: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V [Eur J Pharm Biopharm] 2020 Nov; Vol. 156, pp. 75-83. Date of Electronic Publication: 2020 Aug 19.

Zobrazit plný text záznamu

Akademický článek

Absorption, distribution, metabolism and excretion of darolutamide (a novel non-steroidal androgen receptor antagonist) in rats.

Autor: Taavitsainen P; Orion Corporation Orion Pharma, Turku, Finland., Gieschen H; Division Pharmaceuticals, Bayer AG, Berlin, Germany., Korjamo T; Orion Corporation Orion Pharma, Espoo, Finland., Kähkönen M; Orion Corporation Orion Pharma, Espoo, Finland., Malmström C; Orion Corporation Orion Pharma, Turku, Finland., Prien O; Division Pharmaceuticals, Bayer AG, Berlin, Germany., Niehues M; Division Pharmaceuticals, Bayer AG, Berlin, Germany., Sandmann S; Division Pharmaceuticals, Bayer AG, Wuppertal, Germany., Janssen W; Division Pharmaceuticals, Bayer AG, Wuppertal, Germany., Koskinen M; Orion Corporation Orion Pharma, Espoo, Finland.

Publikováno v: Xenobiotica; the fate of foreign compounds in biological systems [Xenobiotica] 2020 Aug; Vol. 50 (8), pp. 967-979. Date of Electronic Publication: 2020 Feb 06.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Discovery and development of ODM-204: A Novel nonsteroidal compound for the treatment of castration-resistant prostate cancer by blocking the androgen receptor and inhibiting CYP17A1.

Autor: Oksala R; Orion Corporation Orion Pharma, Orionintie 1, FIN-02200, Espoo, Finland. Electronic address: riikka.oksala@orionpharma.com., Moilanen A; Orion Corporation Orion Pharma, Orionintie 1, FIN-02200, Espoo, Finland., Riikonen R; Orion Corporation Orion Pharma, Orionintie 1, FIN-02200, Espoo, Finland., Rummakko P; Orion Corporation Orion Pharma, Orionintie 1, FIN-02200, Espoo, Finland., Karjalainen A; Orion Corporation Orion Pharma, Orionintie 1, FIN-02200, Espoo, Finland., Passiniemi M; Orion Corporation Orion Pharma, Orionintie 1, FIN-02200, Espoo, Finland., Wohlfahrt G; Orion Corporation Orion Pharma, Orionintie 1, FIN-02200, Espoo, Finland., Taavitsainen P; Orion Corporation Orion Pharma, Orionintie 1, FIN-02200, Espoo, Finland., Malmström C; Orion Corporation Orion Pharma, Orionintie 1, FIN-02200, Espoo, Finland., Ramela M; Orion Corporation Orion Pharma, Orionintie 1, FIN-02200, Espoo, Finland., Metsänkylä HM; Orion Corporation Orion Pharma, Orionintie 1, FIN-02200, Espoo, Finland., Huhtaniemi R; Institute of Biomedicine and Turku Center for Disease Modeling, University of Turku, Turku, Finland., Kallio PJ; Orion Corporation Orion Pharma, Orionintie 1, FIN-02200, Espoo, Finland., Mustonen MV; Orion Corporation Orion Pharma, Orionintie 1, FIN-02200, Espoo, Finland. Electronic address: mika.mustonen@orionpharma.com.

Publikováno v: The Journal of steroid biochemistry and molecular biology [J Steroid Biochem Mol Biol] 2019 Sep; Vol. 192, pp. 105115. Date of Electronic Publication: 2018 Feb 10.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání